National Specialty Pharmacy, LLC v. Padhye

Background

National Specialty Pharmacy, LLC described itself as a compounding pharmacy that develops, compounds, markets, and distributes medicines. The complaint named four former employees—Sameer Padhye, Maybelline Sana, Rayne Bridges, and Daniel Brown—along with Coligomed, Inc., Enlil, Inc., and Abhinay Padhye. The complaint alleged that former employees took National Specialty Pharmacy’s confidential information and other property, transferred it to affiliated businesses, modified corporate records without permission, and accessed company systems improperly. These allegations were accepted as true only for purposes of deciding the motions to dismiss.

Four defendants moved to dismiss. Rayne Bridges represented herself and argued that the court lacked personal jurisdiction over her and that the complaint failed to state a claim. Maybelline Sana also challenged personal jurisdiction. Coligomed and Enlil challenged the sufficiency of the claims against them under Federal Rule of Civil Procedure 12(b)(6), which permits dismissal when a complaint does not state a legally sufficient claim.

Rayne Bridges and Maybelline Sana

The court granted Bridges’s motion to dismiss for lack of personal jurisdiction. Bridges stated that she was a Nevada resident, performed no work in California for National Specialty Pharmacy, and had no other California contacts. The court held that the California forum-selection and consent-to-jurisdiction provisions in her employment agreement were unreasonable and unenforceable because the opinion identified no logical connection between California and Bridges’s Nevada employment. The court also found no general or specific personal jurisdiction over her. All claims against Bridges were dismissed under Rule 12(b)(2), which concerns personal jurisdiction, without prejudice to refiling in an appropriate jurisdiction.

The court likewise granted Sana’s motion to dismiss for lack of personal jurisdiction. Sana lived in Nevada, and the court found that the complaint did not identify specific conduct by Sana that was directed toward California and likely to cause harm there. Allegations about California contacts involving other people did not establish jurisdiction over Sana. The court granted Sana’s motion without prejudice to refiling claims against her in an appropriate forum.

Claims Against Coligomed and Enlil

The court granted the companies’ motions to dismiss for failure to state a claim. For tortious interference with a contract, the complaint did not identify the contracts allegedly disrupted or clearly explain which defendants interfered and how. Those claims were dismissed with leave to amend.

The conversion and conspiracy-to-convert claims were also dismissed with leave to amend. The complaint did not identify particular property allegedly converted by either company or specific acts constituting wrongful conversion. The court explained that conspiracy was an alternative theory of liability rather than a separate cause of action.

The court dismissed the claims under the federal Defend Trade Secrets Act with leave to amend. The complaint described alleged trade secrets in broad categories—such as vendor information, formulas, business processes, pricing data, and marketing methods—rather than identifying specific tangible materials. The court directed that any amended complaint identify the specific material claimed to be a trade secret and allege facts showing that Coligomed or Enlil misappropriated it.

The court also dismissed the California Unfair Competition Law claim with leave to amend. The complaint made general assertions that all defendants engaged in unlawful, unfair, fraudulent, deceptive, untrue, and misleading conduct, but did not identify specific actions by Coligomed or Enlil that violated the law.

Disposition

The court granted the defendants’ motions to dismiss. Because it found no personal jurisdiction over Bridges or Sana, those defendants were dismissed from the action. National Specialty Pharmacy could file an amended complaint addressing the deficiencies in its claims against Coligomed and Enlil, with the amended complaint due June 3, 2024, if the company chose to file one. The order resolved pleading and jurisdiction issues and did not determine the ultimate merits of the alleged misconduct.